Cargando…
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
Immunogenicity continues to pose a challenge in the development of biotherapeutics like conventional therapeutic-proteins and monoclonal antibodies as well as emerging modalities such as gene-therapy components, gene editing, and CAR T cells. The approval of any therapeutic is based on a benefit-ris...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213690/ https://www.ncbi.nlm.nih.gov/pubmed/37251396 http://dx.doi.org/10.3389/fimmu.2023.1151888 |